Sagimet Biosciences Announces Oral Presentation on Denifanstat at Keystone Symposia in Nonalcoholic Steatohepatitis (NASH)

SAN MATEO, Calif.--(BUSINESS WIRE)-- #Clinicaltrials--Sagimet Biosciences, a clinical-stage biopharmaceutical company developing novel therapeutics targeting dysfunctional metabolic pathways, announced today that it will present additional Phase 2a data highlighting improved lipid composition and potential cardiovascular benefits of denifanstat in nonalcoholic steatohepatitis (NASH) patients. Denifanstat (formerly TVB-2640), the company’s lead product candidate,...

Click to view original post